CLO25-058: First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia

20250 citationsJournal Article

Authors

Anjali S. Advani · Cleveland Clinic

Olatoyosi Odenike · University of Chicago

Deepa Jeyakumar · Newport (United States)

Raya Mawad · Swedish Medical Center

Olga Frankfurt · Northwestern University

Jiuhong Zha · AbbVie (United States)

Jason G. Harb ·

Abstract

"CLO25-058: First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia" published on 28 Mar 2025 by National Comprehensive Cancer Network.

Topics & Keywords

Protein Degradation and Inhibitors Multiple Myeloma Research and Treatments Chronic Myeloid Leukemia Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of the National Comprehensive Cancer Network

Volume 23, Issue 3.5

DOI: 10.6004/jnccn.2024.7122

Field-Weighted Citation Impact: 0.00